Protective antigen of Epstein Barr Virus

Details Protective antigen of Epstein Barr Virus Protective antigen of Epstein Barr Virus

2006-02-28

2006-02-28

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S196110, C424S093200, C435S325000

Reexamination Certificate

active

07005131

ABSTRACT:
The present invention relates to the identification of a subunit vaccine to prevent or treat infection of Epstein Barr Virus. In particular, EBNA-1 was identified as a vaccine antigen. In a specific embodiment, a purified protein corresponding to EBNA-1 elicited a strong CD4+T cell response. The responsive CD4+T cell are primarily TH1 in function. EBNA-1 is an attractive candidate for a protective vaccine against EBV, and for immunotherapy of EBV infection and neoplasms, particularly with dendritic cells charged with EBNA-1.

REFERENCES:
patent: 5851756 (1998-12-01), Steinman et al.
patent: 2180193 (1996-12-01), None
patent: 96 02563 (1996-02-01), None
patent: 97 24447 (1997-07-01), None
Wong, C. et al., “Induction of Primary, Human Antigen-Specific Cytoxic T Lymphocytes In Vitro Using Dendritic Cells Pulsed with Peptides” (1998) Journal of Immunotherapy, 21(1):32-40.
Romani, et al., “Proliferating Dendritic Cell Progenitors in Human Blood” (1994) J Exp. Med. vol. 180: 83-93.
O'Doherty, et al. “Dendritic Cells Freshly Isolated from Human Blood Express CD4 and Mature into Typical Immunostimulatory Dendritic Cells After Culture in Monocyte-condition Medium”, J. Exp. Med., vol. 178, Sep. 1993, PP. 1067-1078.
Rickinson AB and Kieff E., “Epstein-Barr Virus” In: Fields Virology, 3d Ed. 1996 pp. 2397-2448.
Blake, et al., Immunity, 7:791-802, 1997.
Chen, et al., J. Gen. Virol., 80:447-455, 1999.
Gutierrez, et al., J. Gen. Virol., 78:1663-70, 1997.
Inaba, et al., J. Exp. Med., 188:2163-73, 1998.
Khanna, et al., Eur. J. Immunol., 28:451-458, 1998.
Lee, et al., Eur. J. Immunol., 26:1875-83, 1996.
Levitskaya, et al., Nature, 375 685-688, 1995.
Rickinson and Moss, Ann. Rev. Immunol., 15:405-31, 1997.
Steinman, Exper. Hematol., 24:859-862, 1996.
Steven, et al., J. Exp. Med., 184:1801-13, 1996.
Yates, et al., Nature, 313:815, 1985.
Thomson, S.A. et al., “Targeting a Polyepitope Protein Incorporating a Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition bu CD4 + Cytoxic T Lymphocytes: A Novel Approach to Vaccine Design”, Journal of Virology, vol. 72, No. 3, Mar. 1998, pp. 2246-2252.
Khanna, R. et al., “Targeting Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) Through The Class ll Pathway Restores Immune Recognition by EBNA1 —Specific Cytoxic T Lymphocytes: Evidence for HLA-DM-Independent Processing”, International Immunology, vol. 9, No. 10, Oct. 1997, pp. 1537-1543.
Murray, R.J. et al., “Identification of Target Antigens for the Human Cytotoxic T Cell Response to Epstein-Barr Virus (EBV): Implications for the Immune Control of EBV-Positive Malignancies”, Journal of Experimental Medicine, vol. 176, No. 1, Jul. 1, 1992, pp. 157-168.
Di Nicola, M. et al., “Gene Transfer into Human Dendritic Antigen-Presenting Cells by Vaccinia Virus and Adenovirus Vectors”, Cancer Gene Therapy, vol. 5, No. 6, Nov. 1998, pp. 350-356.
Khanna, R. et al., “Vaccine Strategies Against Epstein-Barr Virus-Associated Diseases:Lessons from Studies on Cytotoxic T-Cell-Mediated Immune Regulation”, Immunological Reviews, vol. 170, Aug. 1999, pp. 49-64.
Tarte, K. et al., “Dendritic Cell-Based Vaccine: A Promising Approach for Cancer Immunotherapy”, Leukemia, vol. 13, No. 5, May 1999, pp. 653-663.
Münz, C. et al., “Human CD4(+) T Lymphocites Consistently Respond to the Latent epstein-barr Virus Nuclear Antigen EBNA1”, Journal of Experimental Medicine, vol. 107, No. 10, May 15, 2000, pp. 1649-1660.
Bickham, K. et al., “EBNA1-Specific CD4 + T Cells in Healthy Carriers of Epstein-Barr Virus are Primarily TH1 in Function”, Journal of Clinical Investigation, vol. 107, No. 1, Jan. 2001, pp. 121-130.

Affiliated with

Also associated with

Rating

Protective antigen of Epstein Barr Virus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protective antigen of Epstein Barr Virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protective antigen of Epstein Barr Virus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3661480